# A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

> **NCT06155084** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hinova Pharmaceuticals Inc.** · enrollment: 84 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** HP518 - Dose Escalation
- **DRUG:** HP518 - Dose Escalation
- **DRUG:** HP518 -Dose Expansion

## Key facts

- **NCT ID:** NCT06155084
- **Lead sponsor:** Hinova Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-26
- **Primary completion:** 2026-03
- **Final completion:** 2026-09
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06155084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06155084, "A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06155084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*